Vimseltinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 14 mg; 20 mg; 30 mg
Reference Brands: Romvimza
Category:
Oncology Cancer Care
Vimseltinib is used in adults to treat giant cell tumor of the tendon sheath (also called tenosynovial giant cell tumor) that is not likely to improve with surgery. Before taking this medicine, tell your doctor if you have or have ever had an allergy to aspirin or food dye or liver disease.
Vimseltinib can harm an unborn baby if the mother or the father is using vimseltinib.
Vimseltinib is available in Capsules
and strengths such as 14 mg; 20 mg; 30 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Vimseltinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Vimseltinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Vimseltinib, an investigational oncology drug, is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality according to GMP standards. In the US, regulatory review involves validation, safety assessments, and clinical trial data submission. In the EU, approval processes include validation, stability testing, and conformity with MDR standards. These dossiers encompass safety profiles, clinical trial results, and manufacturing practices
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing